Asia-Pacific Malaria Treatment Market, By Agent (Plasmodium Falciparum, P. Vivax, P. Ovale, P. Malariae and P. Knowlelsi), Type (Medication and Vaccination), Treatment Type (Suppressive Treatment and Radical Treatment), Drug Type (Branded and Generics), Route of Administration (Oral and Parenteral), End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) – Industry Trends and Forecast to 2030.
Asia-Pacific Malaria Treatment Market Analysis and Size
The malaria treatment market is increasing because of the high prevalence of malaria and several malaria elimination programs by numerous international and national organizations. In 2010, 13 countries in the region reported a high occurrence of malaria with 1,000 or more cases per 100,000 population. The major market players are focusing primarily on expanding and diversifying their market presence and acquiring new customer base, thus prevailing business opportunities.
Data Bridge Market Research analyses a growth rate in the malaria treatment market in the forecast period 2023-2030. The expected CAGR of malaria treatment market is tend to be around 5.1% in the mentioned forecast period. The market was valued at USD 514.52 million in 2022, and it would grow upto USD 766 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific Malaria Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Agent (Plasmodium Falciparum, P. Vivax, P. Ovale, P. Malariae and P. Knowlelsi), Type (Medication and Vaccination), Treatment Type (Suppressive Treatment and Radical Treatment), Drug Type (Branded and Generics), Route of Administration (Oral and Parenteral), End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
|
|
Countries Covered
|
China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam, and Rest of Asia-Pacific
|
|
Market Players Covered
|
Actiza Pharmaceutical Private Limited (India), Amneal Pharmaceuticals LLC. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Cipla Inc. (India), Lupin (India), Ipca Laboratories Ltd (India), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Zydus Group (India), MMV (Switzerland), Novartis AG (Switzerland), Sumaya Biotech (Germany), Taj Pharmaceuticals Limited (India), OSIVAX (France), Strides Pharma Science Limited (India)
|
|
Market Opportunities
|
|
Market Definition
Malaria is a type of deadly infectious disease caused by the Plasmodium parasite. The numerous medication categories for malaria treatment include mefloquine, quinine, chloroquine, primaquine, artemisinin-based combination therapy (ACT), hydroxychloroquine, non-artemisinin based combinations (non-acts) and others. The occurrence of a wide range of malaria treatment products will provide a better patient experience and decrease the risk of death.
Asia-Pacific Malaria Treatment Market Dynamics
Drivers
- Growing Prevalence of Malaria
According to WHO, in 2012, India has the highest prevalence of malaria in this region with an estimated 24 million cases each year,which Indonesia, Pakistan, Myanmar, and Papua New Guinea follow. In the 22 countries in Asia and the Pacific where the disease is predominant, above 80% of the population is at higher risk of getting malaria. Apart from this, the growing number of traveller malaria cases is also leading to the demand for the malaria treatment modalities, as each year, thousands of people travel to the malaria-affected region.
- Growing Demand of Direct Tender Channel
The direct tender segment is contributing to the malaria treatment market as direct tender holds the largest market share combined with the highest CAGR. It is mainly because most of the service providers buy the product from several manufacturers and it is noticed that revenue from direct sales is more influential and growing in the malaria treatment market.
Opportunities
- Increasing Diagnostic Tests For Malaria
various companies are manufacturing rapid diagnostic tests with high sensitivity. For instance, in November 2020, several researchers from Rice University came up with a simple microneedle patch similar to a bandage to detect malaria, to decrease the burden of disease in countries struggling with poor health infrastructure. The microneedles in the patch collect interstitial fluid containing few biomarkers that help detect malaria.
- Increasing Strategic Alliances and Agreements
There have been increasing alliances and agreements between organizations that lead to the immense growth of the market. For instance, in May 2020, ADVANZ PHARMA Corp. Limited entered into an agreement to acquire Correvio Pharma Corp, a specialty pharmaceutical company. The acquisition provided ADVANZ PHARMA with an immediate and direct commercial presence in France, Spain, Germany, Italy, and the Benelux region.
Restraints/Challenges
- Emerging Quality Issues of Drugs
Numerous quality issues associated with malaria drug preparations are also anticipated to impede growth of the market. Several manufacturers are not obtaining WHO prequalification for manufacturing of malaria treatment drugs, leading to the production of substandard quality drugs in the market.
This malaria treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the malaria treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Asia-Pacific Malaria Treatment Market
The COVID-19 outbreak has boosted the demand for several anti-malarial medications, globally, supporting to the growth of malaria treatment market. For instance, on March 30, 2020, USFDA, issued an emergency use authorization (EUA), which allows the use of hydroxychloroquine and chloroquine products used for the treatment of adolescent and adult patients with COVID-19 who have been hospitalized. In march 2018, Bayer AG donated 3 million tablets of its chloroquine phosphate formulation, Resochin, that demonstrated potential for treating the coronavirus infection. Such types of government and companies’ initiatives are playing essential role in the growth the malaria treatment market.
Recent Developments
- In December 2021, Zydus Cadila announced the plan for the antimalarial drug ZY19489 with Medicines For Malaria Venture which received U.S.FDA Approval.
Asia-Pacific Malaria Treatment Market Scope
The malaria treatment market is segmented on the basis of agent, type, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Agent
- Plasmodium Falciparum
- P. Vivax
- P. Ovale
- P. Malariae
- P. Knowlelsi
Type
- Medication
- Vaccination
Treatment Type
- Suppressive Treatment
- Radical Treatment
Route of Administration
- Oral
- Parenteral
End User
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Others
Distribution Channel
- Direct Tender
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Malaria Treatment Market Regional Analysis/Insights
The malaria treatment market is analyzed and market size insights and trends are provided by agent, type, treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the malaria treatment market report are China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam, and Rest of Asia-Pacific.
India is the fastest growing region as the demand for malaria treatment are increasing very rapidly due to growing healthcare expenditure and increasing awareness regarding the malaria vector-borne disease symptoms.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Malaria Treatment Market Share Analysis
The malaria treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to malaria treatment market.
Key players operating in the malaria treatment market include:
- Actiza Pharmaceutical Private Limited (India)
- Amneal Pharmaceuticals LLC. (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Cipla Inc. (India)
- Lupin (India)
- Ipca Laboratories Ltd (India)
- Mylan N.V. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Zydus Group (India)
- MMV (Switzerland)
- Novartis AG (Switzerland)
- Sumaya Biotech (Germany)
- Taj Pharmaceuticals Limited (India)
- OSIVAX (France)
- Strides Pharma Science Limited (India)
SKU-